Virtus ETF Advisers LLC Next Cure, Inc. Transaction History

Virtus ETF Advisers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$7.6 - $10.28 $185,584 - $251,027	-24,419 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $4,257 - $6,023	434 Added 1.81%	24,419 $244,000
Q4 2020 Feb 12, 2021	BUY	$9.47 - $12.43 $104,141 - $136,692	10,997 Added 84.67%	23,985 $261,000
Q3 2020 Nov 13, 2020	SELL	$8.15 - $21.17 $14,319 - $37,195	-1,757 Reduced 11.92%	12,988 $114,000
Q2 2020 Aug 05, 2020	BUY	$21.19 - $40.2 $165,557 - $314,082	7,813 Added 112.71%	14,745 $316,000
Q1 2020 May 14, 2020	SELL	$32.32 - $58.37 $32,158 - $58,078	-995 Reduced 12.55%	6,932 $257,000
Q4 2019 Feb 13, 2020	BUY	$25.0 - $92.22 $198,175 - $731,027	7,927 New	7,927 $447,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.